High-Dose Vitamin B3 Shows Early Promise in Glioblastoma Treatment

A small clinical trial has found that high-dose vitamin B3, also known as niacin, may improve outcomes for patients with glioblastoma, a highly aggressive brain cancer. Eighty-two percent of participants remained free of disease progression for six months after receiving the supplement alongside standard treatment.

Researchers hypothesize that niacin could help reinvigorate immune cells that are typically suppressed by glioblastoma tumors. This potential mechanism may offer a new avenue for supporting existing therapies, though further investigation is required to validate these findings.

The study, while promising, involved a limited number of patients. Larger trials are necessary to determine the long-term safety, effectiveness, and optimal dosing of niacin in this context. Scientists emphasize that it is not yet a standalone treatment but a possible adjunct to current care.

Experts caution that more research is needed before niacin can be widely recommended as part of glioblastoma treatment protocols. The results highlight the need for continued exploration of nutritional interventions in oncology.

Based on reporting from ScienceDaily (Cancer).

Source: ScienceDaily (Cancer). This article was drafted by AI from that reporting and reviewed by an automated accuracy check before publishing.